Showing results (141-150 of 165) with videos related to

Sort By:
Pageof 17
Blood|October 7, 2025
Genomic determinants of response and resistance to pirtobrutinib in relapsed/refractory chronic lymphocytic leukemiaJennifer R Brown, Bastien Nguyen, Sai Prasad Desikan, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 8, 2021
Umbralisib, a Dual PI3Kδ/CK1ε Inhibitor in Patients With Relapsed or Refractory Indolent LymphomaNathan H Fowler, Felipe Samaniego, Wojciech Jurczak, et al.
Blood Advances|August 22, 2025
Pirtobrutinib, a Highly Selective, Non-covalent (Reversible) BTKi in R/R Follicular Lymphoma: Phase 1/2 BRUIN StudyNirav N Shah, Pier Luigi Zinzani, Michael L Wang, et al.
Blood|July 5, 2022
Ibrutinib improves survival compared with chemotherapy in mantle cell lymphoma with central nervous system relapseChiara Rusconi, Chan Y Cheah, Toby A Eyre, et al.
Blood Neoplasia|June 24, 2025
Outcomes for high-risk defining events in follicular lymphoma following frontline immunochemotherapyJoshua W D Tobin, Venkata A Chikatamarla, Marko Matic, et al.
Blood Advances|May 5, 2026
Safety and efficacy of allogeneic CD19-directed CAR-T therapy CTX110 in relapsed/refractory B-cell non-Hodgkin lymphomaJoseph P McGuirk, Armin Ghobadi, Carlos R Bachier, et al.
Internal Medicine Journal|May 17, 2020
Australian and New Zealand consensus statement on the management of lymphoma, chronic lymphocytic leukaemia and myeloma during the COVID-19 pandemicPietro Di Ciaccio, Georgia McCaughan, Judith Trotman, et al.
Blood Advances|October 2, 2019
Outcomes of stage I/II follicular lymphoma in the PET era: an international study from the Australian Lymphoma AllianceJoshua W D Tobin, Gabrielle Rule, Katherine Colvin, et al.
Blood Advances|January 16, 2026
Pirtobrutinib, a Highly Selective, Non-covalent (Reversible) BTKi in R/R Marginal Zone Lymphoma: Phase 1/2 BRUIN StudyKrish Patel, Julie M Vose, Sunita D Nasta, et al.
Blood Advances|September 21, 2021
Integrated safety analysis of umbralisib, a dual PI3Kδ/CK1ε inhibitor, in relapsed/refractory lymphoid malignanciesMatthew S Davids, Owen A O'Connor, Wojciech Jurczak, et al.
Pageof 17